Immatics reels in $75M from Celgene in first cell therapy deal

Immatics netted its largest upfront cash haul yet in an option deal with Celgene to develop TCR-based cell therapies to treat solid tumors.

The $75 million upfront payment is the largest one-time cash infusion for the German biotech across five deals and five financing rounds...